Patents Examined by Gyan Chandra
  • Patent number: 11980655
    Abstract: Stable liquid formulations of GLP-1 and GLP-1 analogues and method of using such formulations in the treatment of disorders or conditions are provided.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: May 14, 2024
    Assignee: Rose Pharma Inc.
    Inventors: Andrea Hawe, Eva Keilhauer, Olimpia Popko, Enda Kenny, Richard Warburg
  • Patent number: 11980656
    Abstract: An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: May 14, 2024
    Assignee: MannKind Corporation
    Inventors: Marshall Grant, Simon R. Bruce, Robert A. Baughman
  • Patent number: 11975049
    Abstract: The invention provides reagents, pharmaceutical compositions and methods for the treatment of prevention of disorders and diseases related to defects in trigeminal innervation of the cornea, stem cell deficiency, nonhealing epithelial wounds and particularly to diseases such as neurotrophic keratopathy.
    Type: Grant
    Filed: February 16, 2021
    Date of Patent: May 7, 2024
    Inventor: Michael C. Struck
  • Patent number: 11976282
    Abstract: Methods and compositions using dnayzme-based GATA3 inhibitors for the treatment of insulin resistance and Type II diabetes, for the stimulation of adipogenesis in vivo, and for the promotion of fat redistribution are disclosed.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: May 7, 2024
    Assignee: QATAR UNIVERSITY
    Inventors: Mohamed Elrayess, Layla Almansoori
  • Patent number: 11970523
    Abstract: The present invention discloses a polypeptide and application thereof. By modifying oxyntomodulin (OXM), hybridizing OXM with a peptide sequence of Exenatide, including enabling the polypeptide to be resistant to DPP-4 enzyme degradation through amino acid modification, and conjugating fatty acid chains at the same time, an OXM hybrid peptide having longer pharmacologic action time and better weight losing effects is obtained. Synthesis of a target polypeptide is fast realized by an orthogonal protection strategy solid-phase synthesis method, and a crude product is purified and freeze-dried to obtain the OXM hybrid peptide.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: April 30, 2024
    Assignee: CHINA PHARMACEUTICAL UNIVERSITY
    Inventors: Hai Qian, Wenlong Huang, Xingguang Cai, Chengye Li, Chunxia Liu, Yuxuan Dai
  • Patent number: 11964016
    Abstract: The present disclosure provides methods for treating allergy comprising selecting a patient with an allergy and administering a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor (e.g., an anti-IL-4 receptor antibody or antigen-binding fragment thereof) in combination with a therapeutically effective amount of an agent that depletes plasma cells (e.g., an anti-BCMA/anti-CD3 bispecific antibody). In certain embodiments, a plasma cell ablating agent such as an anti-BCMA/anti-CD3 bispecific antibody ablates the plasma cells, including IgE+ plasma cells, while the IL-4/IL-13 pathway inhibitor prevents the generation of new IgE+ plasma cells, thus eliminating allergen-specific IgE in the patient.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: April 23, 2024
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Seblewongel Asrat, Andre Limnander, Jamie Orengo, Andrew J. Murphy, George D. Yancopoulos
  • Patent number: 11931418
    Abstract: A method for treating or preventing one or more symptoms of severe inflammation in the lung of a subject in need thereof includes administering to the subject a composition comprising dendrimers complexed, covalently conjugated, or intra-molecularly dispersed or encapsulated with one or more therapeutic or prophylactic agents, in an amount effective to treat, alleviate or prevent one or more symptoms of severe inflammation. The compositions and methods are useful for treating disorders characterized by cytokine storm, for example, for treating or preventing acute lung injury (ALI) and/or acute respiratory distress syndrome (ARDS) results in from ventilator use or infection such as with COVID-19, sepsis, and systemic bacterial infections in a subject in need thereof have been established. Preferably, the dendrimers are generation 4, 5, 6, 7, or 8 poly(amidoamine) (PAMAM) dendrimers, and the therapeutic agents are one or more anti-inflammatory and/or anti-oxidant agents such as N-acetyl cysteine.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: March 19, 2024
    Assignee: Ashvattha Therapeutics, Inc.
    Inventors: Jeffrey L. Cleland, Kannan Rangaramanujam, Sujatha Kannan, Jay Zaveri
  • Patent number: 11931404
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: April 26, 2021
    Date of Patent: March 19, 2024
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci
  • Patent number: 11919935
    Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: March 5, 2024
    Assignee: Akston Biosciences Corporation
    Inventors: Thomas M. Lancaster, Todd C. Zion
  • Patent number: 11911482
    Abstract: Disclosed herein are self-assembling protein nanoparticles comprising passenger molecules of interest.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: February 27, 2024
    Assignee: The Regents of the University of California
    Inventors: Todd Yeates, Yen-Ting Lai, Justin Miller, Phillip Nguyen, Yashes Srinivasan, Nithin Dharmaraj, Scott Taylor, Andrew Liu
  • Patent number: 11896673
    Abstract: Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with glucose, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo. In some embodiments, the delivery vehicle can include: 1) intravenously injectable polymeric nanoparticles (˜100 nm in diameter) coated with RBC membrane and loaded with glucose-modified insulin and/or 2) painless microneedle (MN) patches loaded with the complex of GLUT and glucose-modified insulin.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: February 13, 2024
    Assignee: North Carolina State University
    Inventors: Zhen Gu, Chao Wang
  • Patent number: 11890321
    Abstract: Disclosed herein are a means to prevent and/or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: February 6, 2024
    Assignees: President and Fellows of Harvard College, The Brigham and Women's Hospital, Inc.
    Inventors: Ornella Barrandon, Tommaso Poggioli, Douglas A. Melton, Richard T. Lee
  • Patent number: 11891425
    Abstract: The invention includes a thioamide-modified peptide, wherein the thioamide modification increases the in vivo half-life of the peptide. The invention further includes methods of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering to the subject a thioamide-modified peptide of the invention.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: February 6, 2024
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: E. James Petersson, Alan Saghatelian
  • Patent number: 11890325
    Abstract: The present invention relates to methods for reducing the risk of major adverse cardiovascular events in type 2 diabetes mellitus (T2DM) patients with multiple cardiovascular risk factors without established cardiovascular disease or with established cardiovascular disease comprising administering the glucagon like peptide-1 (GLP-1) receptor agonist dulaglutide.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: February 6, 2024
    Assignee: ELI LILLY AND COMPANY
    Inventors: Jeffrey S. Riesmeyer, David Bradley Woodward
  • Patent number: 11879001
    Abstract: The present invention relates to an IL-2 protein sequence of the formula Ala-SEQ A-Cys*-SEQ B (I), wherein SEQ A has at least 94% sequence identity to SEQ ID NO:1; SEQ B has at least 94% sequence identity to SEQ ID NO:2; Ala is an alanine residue; and Cys* is a cysteine residue; to conjugates thereof and their uses in the treatment of cancer.
    Type: Grant
    Filed: November 3, 2022
    Date of Patent: January 23, 2024
    Assignee: ASCENDIS PHARMA ONCOLOGY DIVISION A/S
    Inventors: Nina Gunnarsson, Matiss Maleckis, David B. Rosen
  • Patent number: 11866491
    Abstract: Disclosed is an antibody capable of binding to the interleukin 4 (IL-4) receptor (IL-4). Also disclosed are a nucleic acid sequence encoding the antibody, a vector including the nucleic acid sequence, and a host cell transformed or transfected with the vector. Provided are a method for producing the antibody, a medical use of the antibody, and a kit including the antibody.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: January 9, 2024
    Assignee: SuZhou Connect Biopharmaceuticals, Inc.
    Inventors: Wei Zheng, Wubin Pan, Xin Yang, Yang Chen, Limin Zhang, Jie Jiang
  • Patent number: 11858975
    Abstract: The present disclosure belongs to the field of biopharmaceuticals, and in particular, relates to a multi-domain active protein for treating metabolic diseases. The multi-domain active protein has a structural formula as shown in Formula I: A-La-F-Lb-B. The multi-domain active protein of the present disclosure has a long half-life and supports a once-a-week administration frequency. The GLP-1R agonist activity of the multi-domain active protein is increased up to over 200 times. The multi-domain active protein has good stability in vitro and in vivo, and shows low immunogenicity potential. As introduction of non-natural amino acids is not required and chemical synthesis and crosslinking steps are not involved, the multi-domain active protein can be prepared recombinantly. Therefore, the preparation process is greatly simplified.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: January 2, 2024
    Assignee: ZHEJIANG DOER BIOLOGICS CORPORATION
    Inventor: Yanshan Huang
  • Patent number: 11844867
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: December 19, 2023
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Patent number: 11845781
    Abstract: The present disclosure discloses a preparation method and use of a double-target fusion protein, and belongs to the technical field of medicines. According to the present disclosure, a novel fusion protein is obtained by transforming an FGF19 sequence and fusing the FGF19 sequence with GLP-1. Compared with wild-type FGF19 and GLP-1, the novel fusion protein has a more long-acting and stable effect, further reduces the carcinogenic risk of FGF19, and can better relieve liver damage and correct metabolic disorder, obesity, overweight, metabolic syndrome, diabetes, dyslipidemia and other diseases. Besides, in treatment, there are no side effects of gastrointestinal discomforts such as diet decline caused by GLP-1 treatment. Therefore, the double-target fusion protein has a wide application prospect.
    Type: Grant
    Filed: March 10, 2023
    Date of Patent: December 19, 2023
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Shenglong Zhu, Yongquan Chen, Zhen Wang
  • Patent number: 11840560
    Abstract: Prodrug compounds of GLP-1/GIP receptor co-agonists are provided wherein the GLP-1/GIP receptor co-agonists have been modified by the linkage of a dipeptide to the GLP-1/GIP receptor co-agonist through an amide bond. The prodrugs disclosed herein have extended half-lives and are converted to the active GLP-1/GIP receptor co-agonist at physiological conditions through a non-enzymatic reaction driven by chemical instability.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: December 12, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Patrick James Knerr, Brian Patrick Finan